STAT3: A novel molecular mediator of resistance to chemoradiotherapy

Cancers

Volumn 6, Issue 4, 2014, Pages 1986-2011

  Spitzner, Melanie ^a   Ebner, Reinhard ^b   Wolff, Hendrik A ^a   Michael Ghadimi, B ^a   Wienands, JüRgen ^a   Grade, Marian ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemoradiotherapy; Chemoradiotherapy resistance; Chemoradiotherapy sensitization; Molecular target; Radiotherapy; STAT3

Indexed keywords

3,3' DIINDOLYLMETHANE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; BARICITINIB; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CEPHARANTHINE; CUCURBITACIN; FEDRATINIB; FLUOROURACIL; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE INHIBITOR; LESTAURTINIB; LINIFANIB; MOMELOTINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NEUTRALIZING ANTIBODY; PACRITINIB; PANITUMUMAB; PROTEIN TYROSINE PHOSPHATASE SHP 2; RESVERATROL; RUXOLITINIB; SORAFENIB; STAT3 PROTEIN; TOFACITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 019;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELLULAR DISTRIBUTION; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; GAMMA RADIATION; GENE SILENCING; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS FREE SURVIVAL; MYELOFIBROSIS; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RADIATION DOSE; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN CANCER; STAT3 GENE; SURVIVAL TIME; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER;

EID: 84907617782     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6041986     Document Type: Review

References (160)

1. Rodel, C.; Liersch T.; Becker H.; Fietkau R.; Hohenberger W.; Hothorn T.; Graeven U.; Arnold D.; Lang-Welzenbach M.; Raab H.R. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012, 13, 679–687.
2. Jagsi, R. Progress and controversies: Radiation therapy for invasive breast cancer. CA Cancer J. Clin. 2013, 64, 135–152.
3. Reck, M.; Heigener D.F.; Mok T.; Soria J.C.; Rabe K.F. Management of non-small-cell lung cancer: Recent developments. Lancet 2013, 382, 709–719.
4. Thariat, J.; Hannoun-Levi J.M.; Sun Myint A.; Vuong T.; Gerard J.P. Past, present, and future of radiotherapy for the benefit of patients. Nat. Rev. Clin. Oncol. 2013, 10, 52–60.
5. Seiwert, T.Y.; Salama J.K.; Vokes E.E. The concurrent chemoradiation paradigm—General principles. Nat. Clin. Pract. Oncol. 2007, 4, 86-100.
6. Katz, D.; Ito E.; Liu F.F. On the path to seeking novel radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 988-996.
7. Begg, A.C.; Stewart F.A.; Vens C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11, 239-253.
8. Shuai, K.; Stark G.R.; Kerr I.M.; Darnell J.E. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993, 261, 1744-1746.
9. Shuai, K.; Ziemiecki A.; Wilks A.F.; Harpur A.G.; Sadowski H.B.; Gilman M.Z.; Darnell J.E. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 1993, 366, 580-583.
10. O'Shea, J.J.; Holland S.M.; Staudt L.M. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl. J. Med. 2013, 368, 161-170.
11. Quintas-Cardama, A.; Verstovsek S. Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and resistance. Clin. Cancer Res. 2013, 19, 1933-1940.
12. Schroder, K.; Hertzog P.J.; Ravasi T.; Hume D.A. Interferon-gamma: An overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75, 163-189.
13. Aaronson, D.S.; Horvath CM. A road map for those who don’t know JAK-STAT. Science 2002, 296, 1653-1655.
14. Darnell, J.E. STATs and gene regulation. Science 1997, 277, 1630-1635.
15. Leonard, W.J. Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol. 2001, 73, 271-277.
16. Hebenstreit, D.; Horejs-Hoeck J.; Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect. 2005, 18, 243-249.
17. Kerr, I.M.; Costa-Pereira A.P.; Lillemeier B.F.; Strobl B. Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett. 2003, 546, 1-5.
18. Greenhalgh, C.J.; Hilton D.J. Negative regulation of cytokine signaling. J. Leukoc. Biol. 2001, 70, 348-356.
19. Krebs, D.L.; Hilton D.J. SOCS proteins: Negative regulators of cytokine signaling. Stem Cells 2001, 19, 378-387.
20. Kim, D.J.; Tremblay M.L.; Digiovanni J. Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS One 2010, 5, e10290.
21. Shuai, K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 2006, 16, 196-202.
22. Faisst, S.; Meyer S. Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res. 1992, 20, 3-26.
23. Levy, D.E.; Lee C.K. What does Stat3 do? J. Clin. Invest. 2002, 109, 1143-1148.
24. Bromberg, J.F.; Wrzeszczynska M.H.; Devgan G; Zhao Y.; Pestell R.G; Albanese C; Darnell J.E. Stat3 as an oncogene. Cell 1999, 98, 295-303.
25. Otero, D.C.; Poli V.; David M.; Rickert R.C. Cutting edge: Inherent and acquired resistance to radiation-induced apoptosis in B cells: A pivotal role for STAT3. J. Immunol. 2006, 177, 6593-6597.
26. Hutchins, A.P.; Diez D.; Miranda-Saavedra D. Genomic and computational approaches to dissect the mechanisms of STAT3’s universal and cell type-specific functions. JAKSTAT 2013, 2, e25097.
27. Chang, Q.; Daly L.; Bromberg J. The IL-6 feed-forward loop: A driver of tumorigenesis. Semin. Immunol. 2014, 26, 48–53.
28. De la Iglesia, N.; Konopka G.; Puram S.V.; Chan J.A.; Bachoo R.M.; You M.J.; Levy D.E.; Depinho R.A.; Bonni A. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008, 22, 449–462.
29. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109, 1139–1142.
30. Chumsri, S.; Shah P. Radiation resistance of cancer stem cells as an obstacle in cancer therapy. Mol. Cell. Pharmacol. 2013, 5, 39–49.
31. Wu, C.T.; Chen M.F.; Chen W.C.; Hsieh C.C. The role of IL-6 in the radiation response of prostate cancer. Radiat. Oncol. 2013, 8, 159.
32. Li, X.; Wang H.; Lu X.; Di B. Silencing STAT3 with short hairpin RNA enhances radiosensitivity of human laryngeal squamous cell carcinoma xenografts in vivo. Exp. Ther. Med. 2010, 1, 947–953.
33. Sun, L.; Cabarcas S.M.; Farrar W.L. Radioresistance and cancer stem cells: Survival of the fittest. J. Carcinog. Mutagen. 2011, S1, 1–12.
34. You, S.; Li R.; Park D.; Xie M.; Sica G.L.; Cao Y.; Xiao Z.Q.; Deng X. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol. Cancer Ther. 2014, 13, 606–616.
35. Panni, R.Z.; Sanford D.E.; Belt B.A.; Mitchem J.B.; Worley L.A.; Goetz B.D.; Mukherjee P.; Wang-Gillam A.; Link D.C.; Denardo D.G. et al. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol. Immunother. 2014, 63, 513–528.
36. Turkson, J.; Jove R. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene 2000, 19, 6613–6626.
37. Wang, X.; Crowe P.J.; Goldstein D.; Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int. J. Oncol. 2012, 41, 1181–1191.
38. Wen, P.Y.; Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507.
39. Siegel, R.; Naishadham D.; Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11–30.
40. Mrugala, M.M. Advances and challenges in the treatment of glioblastoma: A clinician’s perspective. Discov. Med. 2013, 15, 221–230.
41. Tchirkov, A.; Rolhion C.; Bertrand S.; Dore J.F.; Dubost J.J.; Verrelle P. IL-6 gene amplification and expression in human glioblastomas. Br. J. Cancer 2001, 85, 518–522.
42. Birner, P.; Toumangelova-Uzeir K.; Natchev S.; Guentchev M. STAT3 tyrosine phosphorylation influences survival in glioblastoma. J. Neurooncol. 2010, 100, 339–343.
43. Brantley, E.C.; Benveniste E.N. Signal transducer and activator of transcription-3: A molecular hub for signaling pathways in gliomas. Mol. Cancer Res. 2008, 6, 675–684.
44. Zhou, H.; Miki R.; Eeva M.; Fike F.M.; Seligson D.; Yang L.; Yoshimura A.; Teitell M.A.; Jamieson C.A.; Cacalano, N.A. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin. Cancer Res. 2007, 13, 2344–2353.
45. Gao, L.; Li F.; Dong B.; Zhang J.; Rao Y.; Cong Y.; Mao B.; Chen X. Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 1223–1231.
46. Yang, Y.P.; Chang Y.L.; Huang P.I.; Chiou G.Y.; Tseng L.M.; Chiou S.H.; Chen M.H.; Chen M.T.; Shih Y.H.; Chang C.H. et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J. Cell Physiol. 2012, 227, 976–993.
47. Chautard, E.; Loubeau G.; Tchirkov A.; Chassagne J.; Vermot-Desroches C.; Morel L.; Verrelle P. Akt signaling pathway: A target for radiosensitizing human malignant glioma. Neuro-oncology 2010, 12, 434–443.
48. Patel, J.D.; Krilov L.; Adams S.; Aghajanian C.; Basch E.; Brose M.S.; Carroll W.L.; de Lima M.; Gilbert M.R.; Kris M.G. et al. Clinical cancer advances 2013: Annual report on progress against cancer from the American society of clinical oncology. J. Clin. Oncol. 2014, 32, 129–160.
49. Buchholz, T.A. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N. Engl. J. Med. 2009, 360, 63–70.
50. Hoover, S.; Bloom E.; Patel S. Review of breast conservation therapy: Then and now. ISRN Oncol. 2011, 2011, 617593.
51. Watson, C.J.; Miller W.R. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer 1995, 71, 840–844.
52. Garcia, R.; Yu C.L.; Hudnall A.; Catlett R.; Nelson K.L.; Smithgall T.; Fujita D.J.; Ethier S.P.; Jove R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997, 8, 1267–1276.
53. Bowman, T.; Garcia R.; Turkson J.; Jove R. STATs in oncogenesis. Oncogene 2000, 19, 2474–2488.
54. Page, C.; Huang M.; Jin X.; Cho K.; Lilja J.; Reynolds R.K.; Lin J. Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int. J. Oncol. 2000, 17, 23–28.
55. Burke, W.M.; Jin X.; Lin H.J.; Huang M.; Liu R.; Reynolds R.K.; Lin J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001, 20, 7925–7934.
56. Kim, K.W.; Mutter R.W.; Cao C.; Albert J.M.; Shinohara E.T.; Sekhar K.R.; Lu, B. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of survivin following irradiation. Mol. Cancer Ther. 2006, 5, 2659–2665.
57. Kang, Y.; Park M.A.; Heo S.W.; Park S.Y.; Kang K.W.; Park P.H.; Kim J.A. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. Biochim. Biophys. Acta 2013, 1830, 2638–2648.
58. Cunningham, D.; Atkin W.; Lenz H.J.; Lynch H.T.; Minsky B.; Nordlinger B.; Starling N. Colorectal cancer. Lancet 2010, 375, 1030–1047.
59. Sauer, R.; Becker H.; Hohenberger W.; Rodel C.; Wittekind C.; Fietkau R.; Martus P.; Tschmelitsch J.; Hager E.; Hess C.F. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004, 351, 1731–1740.
60. Rodel, C.; Hofheinz R.; Liersch T. Rectal cancer: State of the art in 2012. Curr. Opin. Oncol.2012, 24, 441–447.
61. Spitzner, M.; Emons G.; Kramer F.; Gaedcke J.; Rave-Frank M.; Scharf J.G.; Burfeind P.; Becker H.; Beissbarth T.; Ghadimi B.M. et al. A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78, 1184–1192.
62. Spitzner, M.; Roesler B.; Bielfeld C.; Emons G.; Gaedcke J.; Wolff H.A.; Rave-Frank M.; Kramer F.; Beissbarth T.; Kitz J. et al. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int. J. Cancer 2014, 134, 997–1007.
63. Urick, M.E.; Chung E.J.; Shield W.P.; Gerber N.; White A.; Sowers A.; Thetford A.; Camphausen K.; Mitchell J.; Citrin, D.E. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin. Cancer Res. 2011, 17, 5038–5047.
64. Enzinger, P.C.; Mayer R.J. Esophageal cancer. N. Engl. J. Med. 2003, 349, 2241–2252.
65. Pennathur, A.; Gibson M.K.; Jobe B.A.; Luketich J.D. Oesophageal carcinoma. Lancet 2013, 381, 400–412.
66. Chen, M.F.; Lu M.S.; Lin P.Y.; Chen P.T.; Chen W.C.; Lee K.D. The role of DNA methyltransferase 3b in esophageal squamous cell carcinoma. Cancer 2012, 118, 4074–4089.
67. Chen, M.F.; Chen P.T.; Lu M.S.; Lin P.Y.; Chen W.C.; Lee K.D. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol. Cancer 2013, 12, 26.
68. Cooperberg, M.R.; Broering J.M.; Carroll P.R. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 2010, 28, 1117–1123.
69. Carter, H.B. Management of low (favourable)-risk prostate cancer. BJU Int. 2011, 108, 1684–1695.
70. D’Amico, A.V.; Moul J.; Carroll P.R.; Sun L.; Lubeck D.; Chen M.H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J. Clin. Oncol. 2003, 21, 2163–2172.
71. Mora, L. B.; Buettner R.; Seigne J.; Diaz J.; Ahmad N.; Garcia R.; Bowman T.; Falcone R.; Fairclough R.; Cantor A. et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002, 62, 6659–6666.
72. Smith, Z.L.; Christodouleas J.P.; Keefe S.M.; Malkowicz S.B.; Guzzo T.J. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): A review of the literature and a practical approach to therapy. BJU Int. 2013, 112, 13–25.
73. Meeks, J.J.; Bellmunt J.; Bochner B.H.; Clarke N.W.; Daneshmand S.; Galsky M.D.; Hahn N.M.; Lerner S.P.; Mason M.; Powles T. et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 2012, 62, 523–533.
74. Sun, Y.; Cheng M.K.; Griffiths T.R.; Mellon J.K.; Kai B.; Kriajevska M.; Manson M.M. Inhibition of STAT signalling in bladder cancer by diindolylmethane: Relevance to cell adhesion, migration and proliferation. Curr. Cancer Drug Targets 2013, 13, 57–68.
75. Chen, C.L.; Cen L.; Kohout J.; Hutzen B.; Chan C.; Hsieh F.C.; Loy A.; Huang V.; Cheng G.; Lin J. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol. Cancer 2008, 7, 78.
76. Barbera, L.; Thomas G. Management of early and locally advanced cervical cancer. Semin. Oncol. 2009, 36, 155–169.
77. Duenas-Gonzalez, A.; Zarba J.J.; Patel F.; Alcedo J.C.; Beslija S.; Casanova L.; Pattaranutaporn P.; Hameed S.; Blair J.M.; Barraclough H. et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J. Clin. Oncol. 2011, 29, 1678–1685.
78. Shukla, S.; Shishodia G.; Mahata S.; Hedau S.; Pandey A.; Bhambhani S.; Batra S.; Basir S.F.; Das B.C.; Bharti A.C. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: Implications in high-risk human papillomavirus infection. Mol. Cancer 2010, 9, 282.
79. Chen, H.H.; Chou C.Y.; Wu Y.H.; Hsueh W.T.; Hsu C.H.; Guo H.R.; Lee W.Y.; Su W.C. Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 658–666.
80. Fang, Z.H.; Li Y.J.; Chen Z.; Wang J.J.; Zhu L.H. Inhibition of signal transducer and activator of transcription 3 and cyclooxygenase-2 is involved in radiosensitization of cepharanthine in HeLa cells. Int. J. Gynecol. Cancer 2013, 23, 608–614.
81. Bernier, J.; Domenge C.; Ozsahin M.; Matuszewska K.; Lefebvre J.L.; Greiner R.H.; Giralt J.; Maingon P.; Rolland F.; Bolla M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004, 350, 1945–1952.
82. Cooper, J.S.; Pajak T.F.; Forastiere A.A.; Jacobs J.; Campbell B.H.; Saxman S.B.; Kish J.A.; Kim H.E.; Cmelak A.J.; Rotman M. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004, 350, 1937–1944.
83. Bernier, J.; Cooper J.S. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 2005, 10, 215–224.
84. Song, J.I.; Grandis J.R. STAT signaling in head and neck cancer. Oncogene 2000, 19, 2489–2495.
85. Markovic, A.; Chung C.H. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert. Rev. Anticancer Ther. 2012, 12, 1149–1159.
86. Lai, S.Y.; Johnson F.M. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resist. Updat. 2010, 13, 67–78.
87. Hsiao, J.R.; Jin Y.T.; Tsai S.T.; Shiau A.L.; Wu C.L.; Su W.C. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br. J. Cancer 2003, 89, 344–349.
88. Kotoula, V.; Lambaki S.; Televantou D.; Kalogera-Fountzila A.; Nikolaou A.; Markou K.; Misailidou D.; Syrigos K.N.; Fountzilas G. STAT-Related Profiles are associated with patient response to targeted treatments in locally advanced SCCHN. Transl. Oncol. 2011, 4, 47–58.
89. Masuda, M.; Suzui M.; Yasumatu R.; Nakashima T.; Kuratomi Y.; Azuma K.; Tomita K.; Komiyama S.; Weinstein I.B. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002, 62, 3351–3355.
90. Chen, C.C.; Chen W.C.; Lu C.H.; Wang W.H.; Lin P.Y.; Lee K.D.; Chen, M.F. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, 1214–1224.
91. Chen, Y.W.; Chen K.H.; Huang P.I.; Chen Y.C.; Chiou G.Y.; Lo W.L.; Tseng L.M.; Hsu H.S.; Chang K.W.; Chiou S.H. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma—Derived CD44(+)ALDH1(+) cells. Mol. Cancer Ther. 2010, 9, 2879–2892.
92. Kruser, T.J.; Armstrong E.A.; Ghia A.J.; Huang S.; Wheeler D.L.; Radinsky R.; Freeman D.J.; Harari P.M. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 534–542.
93. Li, X.; Wang H.; Lu X.; Di B. STAT3 blockade with shRNA enhances radiosensitivity in Hep-2 human laryngeal squamous carcinoma cells. Oncol. Rep. 2010, 23, 345–353.
94. Bonner, J.A.; Yang E.S.; Trummell H.Q.; Nowsheen S.; Willey C.D.; Raisch, K.P. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother. Oncol. 2011, 99, 339–343.
95. Adachi, M.; Cui C.; Dodge C.T.; Bhayani M.K.; Lai S.Y. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral. Oncol. 2012, 48, 1220–1226.
96. Pan, Y.; Zhou F.; Zhang R.; Claret F.X. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One 2013, 8, e54565.
97. Goel, A.; Aggarwal B.B. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer 2010, 62, 919–930.
98. Hsu, H.W.; Gridley D.S.; Kim P.D.; Hu S.; de Necochea-Campion R.; Ferris R.L.; Chen C.S.; Mirshahidi S. Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells. Oral. Oncol. 2013, 49, 591–597.
99. Achcar Rde, O.; Cagle P.T.; Jagirdar J. Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: Possible role for chemotherapeutic intervention. Arch. Pathol. Lab. Med. 2007, 131, 1350–1360.
100. Purnell, P.R.; Mack P.C.; Tepper C.G.; Evans C.P.; Green T.P.; Gumerlock P.H.; Lara P.N.; Gandara D.R.; Kung H.J.; Gautschi O. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J. Thorac. Oncol. 2009, 4, 448–454.
101. Sun, Y.; Moretti L.; Giacalone N.J.; Schleicher S.; Speirs C.K.; Carbone D.P.; Lu B. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J. Thorac. Oncol. 2011, 6, 699–706.
102. Lin, Y.C.; Hung M.S.; Lin C.K.; Li J.M.; Lee K.D.; Li Y.C.; Chen M.F.; Chen J.K.; Yang C.T. CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation. Cancer Biother. Radiopharm. 2011, 26, 381–388.
103. Yin, Z.J.; Jin F.G.; Liu T.G.; Fu E.Q.; Xie Y.H.; Sun, R.L. Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J. Surg. Res. 2011, 171, 675–683.
104. Hsu, H.S.; Huang P.I.; Chang Y.L.; Tzao C.; Chen Y.W.; Shih H.C.; Hung S.C.; Chen Y.C.; Tseng L.M.; Chiou S.H. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011, 117, 2970–2985.
105. De Gruijl, F.R.; van Kranen H.J.; Mullenders L.H. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J. Photochem. Photobiol. B 2001, 63, 19–27.
106. Sano, S.; Itami S.; Takeda K.; Tarutani M.; Yamaguchi Y.; Miura H.; Yoshikawa K.; Akira S.; Takeda J. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999, 18, 4657–4668.
107. Kim, D.J.; Chan K.S.; Sano S.; Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol. Carcinog. 2007, 46, 725–731.
108. Sano, S.; Chan K.S.; DiGiovanni J. Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases. J. Dermatol. Sci. 2008, 50, 1–14.
109. Sano, S.; Chan K.S.; Kira M.; Kataoka K.; Takagi S.; Tarutani M.; Itami S.; Kiguchi K.; Yokoi M.; Sugasawa K. et al. Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res. 2005, 65, 5720–5729.
110. Dzwierzynski, W.W. Managing malignant melanoma. Plast. Reconstr. Surg. 2013, 132, 446e–460e.
111. Johnson, G.E.; Ivanov V.N.; Hei T.K. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 2008, 13, 790–802.
112. Bonner, J.A.; Trummell H.Q.; Willey C.D.; Plants B.A.; Raisch K.P. Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. Radiother. Oncol. 2009, 92, 339–344.
113. Karras, J.G.; Wang Z.; Huo L.; Howard R.G.; Frank D.A.; Rothstein T.L. Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J. Exp. Med. 1997, 185, 1035–1042.
114. Sugino, K.; Ito K.; Mimura T.; Nagahama M.; Fukunari N.; Kubo A.; Iwasaki H. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002, 131, 245–248.
115. Zito, G.; Richiusa P.; Bommarito A.; Carissimi E.; Russo L.; Coppola A.; Zerilli M.; Rodolico V.; Criscimanna A.; Amato M. et al. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 2008, 3, e3544.
116. Tseng, L.M.; Huang P.I.; Chen Y.R.; Chen Y.C.; Chou Y.C.; Chen Y.W.; Chang Y.L.; Hsu H.S.; Lan Y.T.; Chen K.H. et al. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J. Pharmacol. Exp. Ther. 2012, 341, 410–423.
117. Huang, C.Y.; Lin C.S.; Tai W.T.; Hsieh C.Y.; Shiau C.W.; Cheng A.L.; Chen K.F. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86, 456–462.
118. Snyder, M.; Huang X.Y.; Zhang, J.J. Identification of novel direct Stat3 target genes for control of growth and differentiation. J. Biol. Chem. 2008, 283, 3791–3798.
119. Haviland, R. Identification of novel STAT3 target genes associated with oncogenesis. PhD Thesis. University of South Florida, Tampa, FL, USA, 2011.
120. Timofeeva, O.A.; Tarasova N.I.; Zhang X.; Chasovskikh S.; Cheema A.K.; Wang H.; Brown M.L.; Dritschilo A. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc. Natl. Acad. Sci. USA 2013, 110, 1267–1272.
121. Bourillot, P.Y.; Aksoy I.; Schreiber V.; Wianny F.; Schulz H.; Hummel O.; Hubner N.; Savatier P. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells 2009, 27, 1760–1771.
122. Courapied, S.; Sellier H.; de Carne Trecesson S.; Vigneron A.; Bernard A.C.; Gamelin E.; Barre B.; Coqueret O. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J. Biol. Chem. 2010, 285, 26765–26778.
123. Barry, S.P.; Townsend P.A.; Knight R.A.; Scarabelli T.M.; Latchman D.S.; Stephanou A. STAT3 modulates the DNA damage response pathway. Int. J. Exp. Pathol. 2010, 91, 506–514.
124. Ushijima, R.; Sakaguchi N.; Kano A.; Maruyama A.; Miyamoto Y.; Sekimoto T.; Yoneda Y.; Ogino K.; Tachibana T. Extracellular signal-dependent nuclear import of STAT3 is mediated by various importin alphas. Biochem. Biophys. Res. Commun. 2005, 330, 880–886.
125. Cimica, V.; Chen H.C.; Iyer J.K.; Reich N.C. Dynamics of the STAT3 transcription factor: Nuclear import dependent on Ran and importin-beta1. PLoS One 2011, 6, e20188.
126. Ma, J.; Cao X. Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell Signal. 2006, 18, 1117–1126.
127. Bhattacharya, S.; Schindler C. Regulation of Stat3 nuclear export. J. Clin. Invest. 2003, 111, 553–559.
128. Gao, J.; McConnell M.J.; Yu B.; Li J.; Balko J.M.; Black E.P.; Johnson J.O.; Lloyd M.C.; Altiok S.; Haura E.B. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int. J. Oncol. 2009, 35, 337–345.
129. Kamran, M.Z.; Patil P.; Gude, R.P. Role of STAT3 in cancer metastasis and translational advances. Biomed. Res. Int. 2013, 2013, 421821.
130. Priester, M.; Copanaki E.; Vafaizadeh V.; Hensel S.; Bernreuther C.; Glatzel M.; Seifert V.; Groner B.; Kogel D.; Weissenberger J. STAT3 silencing inhibits glioma single cell infiltration and tumor growth. Neuro-oncology 2013, 15, 840–852.
131. Wu, Y.; Diab I.; Zhang X.; Izmailova E.S.; Zehner Z.E. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene 2004, 23, 168–178.
132. Colomiere, M.; Ward A.C.; Riley C.; Trenerry M.K.; Cameron-Smith D.; Findlay J.; Ackland L.; Ahmed, N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br. J. Cancer 2009, 100, 134–144.
133. Avtanski, D.B.; Nagalingam A.; Bonner M.Y.; Arbiser J.L.; Saxena N.K.; Sharma, D. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol. Oncol. 2014, 8, 565–580.
134. Ng, I.H.; Yeap Y.Y.; Ong L.S.; Jans D.A.; Bogoyevitch M.A. Oxidative stress impairs multiple regulatory events to drive persistent cytokine-stimulated STAT3 phosphorylation. Biochim. Biophys. Acta 2014, 1843, 483–494.
135. Gough, D.J.; Sehgal P.; Levy D.E. Nongenomic functions of STAT3. In Jak-Stat Signaling: From Basics to Disease; Decker, T., Müller, M., Eds.; Springer Vienna: Vienna, Austria, 2012; pp. 91–98.
136. Zouein, F.A.; Kurdi M.; Booz G.W. Dancing rhinos in stilettos: The amazing saga of the genomic and nongenomic actions of STAT3 in the heart. JAKSTAT 2013, 2, e24352.
137. Wegrzyn, J.; Potla R.; Chwae Y.J.; Sepuri N.B.; Zhang Q.; Koeck T.; Derecka M.; Szczepanek K.; Szelag M.; Gornicka A. et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323, 793–797.
138. Meier, J.A.; Larner A.C. Toward a new STATe: The role of STATs in mitochondrial function. Semin. Immunol. 2014, 26, 20–28.
139. Elschami, M.; Scherr M.; Philippens B.; Gerardy-Schahn, R. Reduction of STAT3 expression induces mitochondrial dysfunction and autophagy in cardiac HL-1 cells. Eur. J. Cell Biol. 2013, 92, 21–29.
140. Yoon, S.; Woo S.U.; Kang J.H.; Kim K.; Kwon M.H.; Park S.; Shin H.J.; Gwak H.S.; Chwae Y.J. STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells. Autophagy 2010, 6, 1125–1138.
141. Zhang, Q.; Raje V.; Yakovlev V.A.; Yacoub A.; Szczepanek K.; Meier J.; Derecka M.; Chen Q.; Hu Y.; Sisler J. et al. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J. Biol. Chem. 2013, 288, 31280–31288.
142. Mackenzie, G.G.; Huang L.; Alston N.; Ouyang N.; Vrankova K.; Mattheolabakis G.; Constantinides P.P.; Rigas B. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One 2013, 8, e61532.
143. Darnell, J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 740–749.
144. Yue, P.; Turkson J. Targeting STAT3 in cancer: How successful are we? Expert Opin. Investig. Drugs 2009, 18, 45–56.
145. Mankan, A.K.; Greten F.R. Inhibiting signal transducer and activator of transcription 3: Rationality and rationale design of inhibitors. Expert Opin. Investig. Drugs 2011, 20, 1263–1275.
146. Nelson, E.A.; Sharma S.V.; Settleman J.; Frank D.A. A chemical biology approach to developing STAT inhibitors: Molecular strategies for accelerating clinical translation. Oncotarget 2011, 2, 518–524.
147. Debnath, B.; Xu S.; Neamati, N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J. Med. Chem. 2012, 55, 6645–6668.
148. Reddy, M.M.; Deshpande A.; Sattler M. Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin. Ther. Targets 2012, 16, 313–324.
149. Harry, B.L.; Eckhardt S.G.; Jimeno A. JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opin. Investig. Drugs 2012, 21, 637–655.
150. Sansone, P.; Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 2012, 30, 1005–1014.
151. Laurie, S.A.; Goss G.D.; Shepherd F.A.; Reaume M.N.; Nicholas G.; Philip L.; Wang L.; Schwock J.; Hirsh V.; Oza A. et al. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: The princess margaret hospital phase II consortium. Clin. Lung Cancer 2014, 15, 52–57.
152. Johnson, F.M.; Saigal B.; Talpaz M.; Donato N.J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. 2005, 11, 6924–6932.
153. Guo, Y.; Xu F.; Lu T.; Duan Z.; Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012, 38, 904–910.
154. NCT01066663, a phase I/II study of pyrimethamine, a STAT3 inhibitor, for the treatment of relapsed chronic lymphocytic Leukemia/small Lymphocytic Lymphoma. Available online: http://clinicaltrials.gov (accessed on 9 February 2010).
155. NCT00529113, a randomized phase I/II study with gemcitabine and RTA 402 or gemcitabine and placebo for patients with unresectable pancreatic cancer. Available online: http://clinicaltrials.gov (accessed on 12 September 2007).
156. Hong, D.S.; Kurzrock R.; Supko J.G.; Lawrence D.P.; Wheler J.J.; Meyer C.J.; Mier J.W.; Andreeff M.; Shapiro G.I.; Dezube B.J. Phase I trial with a novel oral NF-{kappa}B/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies. J. Clin. Oncol. 2008, 26 15S, 3517.
157. Meyer, S.C.; Levine R.L. Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin. Cancer Res. 2014, 20, 2051–2059.
158. Guo, X.; Qiu J.; Tu T.; Yang X.; Deng L.; Anders R.A.; Zhou L.; Fu Y.X. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity 2014, 40, 25–39.
159. Takeda, K.; Noguchi K.; Shi W.; Tanaka T.; Matsumoto M.; Yoshida N.; Kishimoto T.; Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 1997, 94, 3801–3804.
160. Inghirami, G.; Chiarle R.; Simmons W.J.; Piva R.; Schlessinger K.; Levy D.E. New and old functions of STAT3: A pivotal target for individualized treatment of cancer. Cell Cycle 2005, 4, 1131–1133.